Aarkstore || What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline | Market

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) April 15, 2011 -- What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline

Published Date : 1 February 2010

Pages : 220

The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market? This report What's Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched, including the following target areas:

* Addiction
* Allergy
* Alzheimer’s Disease
* Anthrax
* Asthma
* Campylobacter Infection
* Chlamydia
* Croup
* Dengue Fever
* Diabetes
* Ebola
* Epstein-Barr Virus
* Enterotoxigenic Escherichia coli
* Helicobacter Pylori
* Hepatitis
* Herpesvirus
* Hookworm
* Hypertension
* HIV/AIDS
* Leishmaniasis
* Malaria
* MRSA Infection
* Multiple Sclerosis
* Obesity
* Parainfluenza Virus Type 3
* Parkinson’s Disease
* Plague
* Respiratory Syncytial Virus

* Ross River Virus
* Shigellosis
* Smoking
* Stroke
* Tuberculosis
* West Nile Virus

Some of these vaccines may see success; some could be the blockbusters of the future. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Alison Sahoo has looked at the vaccine market three times in as many years for , and in this report applies a knowledge of what companies have done in the past to potential efforts.

There are a number of trends that will impact the industry that market watchers will want to know about, and has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on the emerging vaccine activities of the following companies

* Acambis plc
* ACE BioSciences
* AFFiRiS
* ALK-Abello A/S
* Allergy Therapeutics
* Bavarian Nordic A/S

* Baxter Healthcare
* Celldex Therapeutics
* Crucell
* Cytos Biotechnology Financial GlaxoSmithKline
* Hawaii Biotech
* Intercell
* Medimmune
* Merck & Co. Inc
* Mymetics
* Nabi Biopharmaceuticals
* Novartis
* Opexa Therapeutics
* Paladin Labs
* Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2020. The report does not does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as has an entire report on this topic.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.

For more information please visit :

http://www.aarkstore.com/reports/What-s-Next-in-Vaccines-HIV-Malaria-Rabies-MRSA-and-30-Other-Vaccine-Targets-in-the-2010-2020-Pipeline-37917.html

For More Related Reports Please follow the link :

http://www.aarkstore.com/search/viewresults.asp?search=Vaccine&PubId=&pagenum=1

global market     hiv     malaria     mrsa     Rabies     targets     vaccines